This is an open label randomized controlled clinical trial comparing two regimens for
treatment of smear-positive pulmonary TB, among patients previously treated for TB. The
primary objective is to determine if a moxifloxacin-containing regimen, substituting
moxifloxacin for ethambutol, of 24 weeks duration is superior to a control regimen of 24
weeks duration in improving treatment outcomes in patients with recurrent TB and shortens the
duration of TB treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centre for the AIDS Programme of Research in South Africa
Treatments:
Ethambutol Fluoroquinolones Isoniazid Moxifloxacin Norgestimate, ethinyl estradiol drug combination Pyrazinamide